Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) reached a new 52-week high during trading on Wednesday . The company traded as high as $20.47 and last traded at $20.46, with a volume of 843657 shares trading hands. The stock had previously closed at $19.57.

A number of analysts recently commented on the stock. BMO Capital Markets upped their price objective on shares of Halozyme Therapeutics from $15.00 to $18.00 and gave the company a “market perform” rating in a research report on Wednesday, November 8th. Zacks Investment Research upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a research report on Wednesday, September 27th. Barclays cut shares of Halozyme Therapeutics from an “overweight” rating to a “hold” rating and upped their price objective for the company from $16.00 to $19.00 in a research report on Wednesday, November 22nd. BidaskClub upgraded shares of Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 26th. Finally, Canaccord Genuity upped their price objective on shares of Halozyme Therapeutics from $17.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. Halozyme Therapeutics has a consensus rating of “Hold” and an average price target of $18.50.

The company has a quick ratio of 3.37, a current ratio of 3.46 and a debt-to-equity ratio of 2.01.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.06 by ($0.04). The firm had revenue of $63.73 million for the quarter, compared to the consensus estimate of $58.95 million. Halozyme Therapeutics had a negative return on equity of 892.57% and a negative net margin of 53.17%. Halozyme Therapeutics’s revenue for the quarter was up 100.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.23) EPS. analysts predict that Halozyme Therapeutics, Inc. will post 0.27 EPS for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in HALO. Aperio Group LLC increased its holdings in Halozyme Therapeutics by 99.2% during the 2nd quarter. Aperio Group LLC now owns 28,823 shares of the biopharmaceutical company’s stock worth $370,000 after purchasing an additional 14,353 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Halozyme Therapeutics by 241.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 128,136 shares of the biopharmaceutical company’s stock worth $1,643,000 after buying an additional 90,608 shares during the last quarter. Sei Investments Co. boosted its stake in shares of Halozyme Therapeutics by 8.2% during the 2nd quarter. Sei Investments Co. now owns 335,025 shares of the biopharmaceutical company’s stock worth $4,295,000 after buying an additional 25,300 shares during the last quarter. IFP Advisors Inc boosted its stake in shares of Halozyme Therapeutics by 1.6% during the 2nd quarter. IFP Advisors Inc now owns 14,686 shares of the biopharmaceutical company’s stock worth $188,000 after buying an additional 226 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its stake in shares of Halozyme Therapeutics by 9.9% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 511,806 shares of the biopharmaceutical company’s stock worth $6,562,000 after buying an additional 46,040 shares during the last quarter. Hedge funds and other institutional investors own 84.50% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/halozyme-therapeutics-halo-sets-new-12-month-high-at-20-47/1761810.html.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.